CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

Please provide your email address to receive an email when new articles are posted on . Today the FDA announced the approval of the gonadotropin-releasing hormone receptor inhibitor degarelix for the ...

Patient undergoing cardiovascular check-up. The risk of death from any cause was higher with degarelix. Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared ...